Want to see DGX full AI Analyst Report?
DGX Stock Chart & Stats
$244.51
-$0.04(-0.02%)
At close: 4:00 PM EDT
$244.51
-$0.04(-0.02%)
Day’s Range― - ―
52-Week Range$171.18 - $253.12
Previous CloseN/A
Volume1.54M
Average Volume (3M)1.13M
Market Cap
$27.02B
Enterprise Value$31.99B
Total Cash (Recent Filing)$797.00M
Total Debt (Recent Filing)$6.29B
Price to Earnings (P/E)24.1
Beta<0.01
Next Earnings
Feb 04, 2027EPS Estimate
2.68Next Dividend Ex-DateN/A
Dividend Yield1.38%
Share Statistics
EPS (TTM)10.18
Shares Outstanding110,019,070
10 Day Avg. Volume1,067,567
30 Day Avg. Volume1,134,753
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)2.69
Price to Sales (P/S)1.75
P/FCF Ratio14.17
Enterprise Value/Market Cap1.18
Enterprise Value/Revenue2.70
Enterprise Value/Gross Profit8.15
Enterprise Value/Ebitda13.89
Forecast
1Y Price Target
$259.50Price Target Upside6.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)11.31
Revenue Forecast (FY)$12.09B
Bulls Say, Bears Say
Bulls Say
Broad Revenue And Volume GrowthBroad volume and revenue growth across diagnostic information services indicates sustained demand rather than reliance on a single customer or test category. Continued physician, hospital, and consumer adoption can support operating leverage and strengthen Quest’s position as healthcare utilization expands.
Strong Cash GenerationStrong operating and free cash flow gives Quest internally generated resources to fund laboratory capacity, technology investments, acquisitions, and shareholder returns. Improving free cash flow also provides resilience against reimbursement pressure while supporting ongoing business modernization.
Productivity And Diagnostic InnovationQuest is pairing diagnostic innovation with automation and productivity initiatives, creating multiple avenues for durable efficiency and growth. Advanced testing, AI-enabled laboratory processes, and expanding consumer health services can improve the service mix and support margins over time.
Bears Say
Medicare Reimbursement PressurePAMA rate reductions create a structural reimbursement headwind for a meaningful portion of Quest’s testing portfolio. Management expects to offset some of the effect, but the scale and breadth of code cuts could pressure revenue, pricing power, and margins beyond the immediate quarter.
Cost Inflation And Transformation SpendingPersistent wage inflation and higher fuel costs raise the operating burden across Quest’s laboratory and service-center network. Project Nova adds near-term expense while modernization proceeds, so productivity gains must offset both inflation and transformation spending to sustain margin expansion.
Cybersecurity And Patient-data ExposureUnauthorized access to a system containing patient records creates potential regulatory, remediation, legal, and reputational consequences even though operations have not been materially disrupted. The unresolved scope makes the eventual financial and client impact uncertain over the coming months.
Quest Diagnostics News
DGX FAQ
What was Quest Diagnostics’s price range in the past 12 months?
Quest Diagnostics lowest stock price was $171.18 and its highest was $253.12 in the past 12 months.
What is Quest Diagnostics’s market cap?
Quest Diagnostics’s market cap is $27.02B.
When is Quest Diagnostics’s upcoming earnings report date?
Quest Diagnostics’s upcoming earnings report date is Feb 04, 2027 which is in 97 days.
How were Quest Diagnostics’s earnings last quarter?
Quest Diagnostics released its earnings results on Oct 22, 2026. The company reported $3 earnings per share for the quarter, beating the consensus estimate of $2.875 by $0.125.
Is Quest Diagnostics overvalued?
According to Wall Street analysts Quest Diagnostics’s price is currently Undervalued.
Does Quest Diagnostics pay dividends?
Quest Diagnostics pays a Quarterly dividend of $0.86 which represents an annual dividend yield of 1.38%. See more information on Quest Diagnostics dividends here
What is Quest Diagnostics’s EPS estimate?
Quest Diagnostics’s EPS estimate is 2.68.
How many shares outstanding does Quest Diagnostics have?
Quest Diagnostics has 110,019,070 shares outstanding.
What happened to Quest Diagnostics’s price movement after its last earnings report?
Quest Diagnostics reported an EPS of $3 in its last earnings report, beating expectations of $2.875. Following the earnings report the stock price went up 1.821%.
Which hedge fund is a major shareholder of Quest Diagnostics?
Currently, no hedge funds are holding shares in DGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quest Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$259.50 (6.13% Upside)
$259.50 (6.13% Upside)
Blogger Sentiment
Neutral
DGX Sentiment 50%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 299.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 10.6%
Last 30 Days ▲ 10.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.08%
12-Months-Change
Fundamentals
Return on Equity
15.21%
Trailing 12-Months
Asset Growth
6.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Quest Diagnostics
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
DGX Company Deck
DGX Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive overall, supported by 10% revenue growth, 15.4% adjusted EPS growth, broad organic volume gains, improving margins, strong channel performance, productivity initiatives, and raised full-year guidance. The main negative factors were the expected PAMA revenue headwind, broad anticipated rate cuts, wage and fuel cost pressure, additional Project Nova spending, and an early-stage cybersecurity investigation. Management stated that it intends to offset a portion of the PAMA impact and maintained confidence in utilization and underlying demand.View all DGX earnings summariesDGX Revenue Breakdown
97.73% Diagnostic Information Services
2.27% DS businesses
DGX Stock 12 Month Forecast
Average Price Target
$259.50
▲(6.13% Upside)
Technical Analysis
Ownership Overview
0.45% Insiders
32.01% Mutual Funds
2.67% Other Institutional Investors
35.49% Public Companies and
Individual Investors